文献速递MDS 与骨髓增殖性肿瘤白血病淋巴瘤

骨髓增殖性肿瘤患者的第二恶性肿瘤:一项基于人群的9379例患者队列研究

Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients.
PubMed 文献 · Leukemia · 2018-01-30

基于瑞典全国登记资料,纳入1973至2009年诊断的9379例骨髓增殖性肿瘤(MPN)患者及35682例匹配对照,随访至2010年。MPN患者发生任何非血液系统癌症的风险显著升高(HR 1.6,95%CI 1.5-1.7),急性髓系白血病风险极高(HR 46.0,95%CI 32.6-64.9),淋巴瘤风险亦升高(HR 2.6,95%CI 2.0-3.3),且风险在各MPN亚型、性别和诊断年代间相似。

要点

  • MPN患者非血液系统癌症风险升高,HR 1.6(95%CI 1.5-1.7)。
  • 非黑色素瘤皮肤癌、肾癌、脑癌HR均为2.8。
  • 急性髓系白血病HR 46.0(95%CI 32.6-64.9),淋巴瘤HR 2.6(95%CI 2.0-3.3)。

核心结论

  • 本研究为MPN患者癌症风险升高提供了基于人群的有力证据。

研究设计与样本

  • 基于瑞典全国登记资料的基于人群队列研究,纳入1973至2009年诊断的9379例MPN患者和35682例匹配对照,随访至2010年。
  • 采用Cox回归和灵活参数模型计算风险比(HR)及95%置信区间(CI)。

主要发现

  • 任何非血液系统癌症风险显著升高,HR 1.6(95%CI 1.5-1.7)。
  • 非黑色素瘤皮肤癌HR 2.8(95%CI 2.4-3.3),肾癌HR 2.8(95%CI 2.0-4.0),脑癌HR 2.8(95%CI 1.9-4.2),内分泌癌HR 2.5(95%CI 1.6-3.8),恶性黑色素瘤HR 1.9(95%CI 1.4-2.7),胰腺癌HR 1.8(95%CI 1.2-2.6),肺癌HR 1.7(95%CI 1.4-2.2),头颈癌HR 1.7(95%CI 1.2-2.6)。
  • 血液系统恶性肿瘤风险亦显著升高:急性髓系白血病HR 46.0(95%CI 32.6-64.9),淋巴瘤HR 2.6(95%CI 2.0-3.3)。
  • 第二恶性肿瘤的HR在各MPN亚型、性别和MPN诊断年代间相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To determine the risk of a wide range of second malignancies in patients with myeloproliferative neoplasms (MPNs), we conducted a large population-based study and compared the results to matched controls. From national Swedish registers, 9379 patients with MPNs diagnosed between 1973 and 2009, and 35,682 matched controls were identified as well as information on second malignancies, with follow-up until 2010. Hazard ratios (HRs) with 95 % confidence intervals (CIs) were calculated using Cox regression and a flexible parametric model. There was a significantly increased risk of any non-hematologic cancer with HR of 1.6 (95% CI: 1.5-1.7). The HRs for non-melanoma skin cancer was 2.8 (2.4-3.3), kidney cancer 2.8 (2.0-4.0), brain cancer 2.8 (1.9-4.2), endocrine cancers 2.5 (1.6-3.8), malignant melanoma 1.9 (1.4-2.7), pancreas cancer 1.8 (1.2-2.6), lung cancer 1.7 (1.4-2.2), and head and neck cancer 1.7 (1.2-2.6). The HR of second malignancies was similar across all MPN subtypes, sex, and calendar periods of MPN diagnosis. The risk of developing a hematologic malignancy was also significantly increased; the HR for acute myeloid leukemia was 46.0 (32.6-64.9) and for lymphoma 2.6 (2.0-3.3). In conclusion, our study provides robust population-based support of an increased cancer risk in MPN patients.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Landtblom AR, Bower H, Andersson TM, et al. Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients. Leukemia. 2018. PMID: 29535425. doi:10.1038/s41375-018-0027-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。